A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life  by Cleland, Jeffrey L. et al.
A Novel Long-Acting Human Growth Hormone Fusion Protein
(VRS-317): Enhanced In Vivo Potency and Half-Life
JEFFREY L. CLELAND,1 NATHAN C. GEETHING,2 JEROME A. MOORE,3 BRIAN C. ROGERS,3 BENJAMIN J. SPINK,2
CHAI-WEI WANG,2 SUSAN E. ALTERS,2 WILLEM P. C. STEMMER,2 VOLKER SCHELLENBERGER2
1Versartis, Inc., Redwood City, California
2Amunix, Inc., Mountain View, California
3Pacific BioDevelopment, San Bruno, California
Received 30 March 2012; revised 18 May 2012; accepted 21 May 2012
Published online 7 June 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.23229
ABSTRACT: A novel recombinant human growth hormone (rhGH) fusion protein (VRS-317)
was designed to minimize receptor-mediated clearance through a reduction in receptor bind-
ing without mutations to rhGH by genetically fusing with XTEN amino acid sequences to the
N-terminus and the C-terminus of the native hGH sequence. Although in vitro potency of VRS-
317 was reduced approximately 12-fold compared with rhGH, in vivo potency was increased
because of the greatly prolonged exposure to the target tissues and organs. VRS-317 was three-
fold more potent than daily rhGH in hypophysectomized rats and fivefold more potent than
daily rhGH in juvenile monkeys. In juvenile monkeys, a monthly dose of 1.4mg/kg VRS-317
(equivalent to 0.26mg/kg rhGH) caused a sustained pharmacodynamic response for 1 month
equivalent to 0.05mg/kg/day rhGH (1.4mg/kg rhGH total over 28 days). In monkeys, VRS-317,
having a terminal elimination half-life of approximately 110h, was rapidly and near-completely
absorbed, and was well tolerated with no observed adverse effects after every alternate week
subcutaneous dosing for 14 weeks. VRS-317 also did not cause lipoatrophy in pig and monkey
studies. VRS-317 is currently being studied in GH-deficient patients to confirm the observa-
tions in these animal studies. © 2012 Wiley Periodicals, Inc. and the American Pharmacists
Association J Pharm Sci 101:2744–2754, 2012
Keywords: growth hormone; long acting; growth hormone deficiency; pharmacodynamics;
pharmacokinetics; safety; hormones; protein delivery; glomerular filtration
INTRODUCTION
Recombinant human growth hormone (rhGH) has
been used in the treatment of growth hormone defi-
ciency (GHD) in adults and children since 1986. GHD
patients lack the natural endogenous pulsatile secre-
tion of hGH, and therefore, rhGH is a replacement
therapy. Current rhGH therapy requires daily sub-
cutaneous (s.c.) injections of rhGH resulting in poor
compliance with therapy.1 The pharmacokinetic (PK)
profile of daily rhGH injections does not mimic the
endogeneous multiple daily pulses of hGH, but has
been demonstrated for over 30 years to be a safe
and effective therapy for treatment of GHD. Clinical
studies of continuous infusion of rhGH with a pump
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demonstrate comparable growth velocity and insulin-
like growth factor I (IGF-I) levels to those achieved
with daily rhGH injections.2–4 A continuous infusion
of rhGH has been compared with daily rhGH therapy
in adult GHD patients for 6 months.5 This study indi-
cated that the safety profile and effects on the IGF-I
responses were not significantly different between pa-
tients treated with continuous infusion of rhGH and
daily rhGH therapy. Therefore, continuous, as well as
daily, administration of rhGH appears to be safe and
efficacious.
Several long-acting rhGH products have been
studied in GHD patients over the past 15 years.
The first approved long-acting rhGH product, Nu-
tropin Depot R© (Genentech, Inc, South San Francisco,
California, USA), is no longermarketed because of the
difficulties with manufacturing of the product. Nu-
tropin Depot R© provides a sustained release of rhGH
from a biodegradable polymer similar to that used in
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resorbable sutures.6 The levels of serum hGH sus-
tained in pediatric GHD patients after a single dose
of Nutropin Depot R© are not sufficient to stimulate
growth for the projected monthly dosing interval.7
Another long-acting depot formulation of rhGH con-
sists of rhGH encapsulated in hyaluronic acid poly-
mer (LB03002). LB03002 is designed for weekly dos-
ing and provides a sustained rhGH level sufficient to
stimulate a pharmacodynamics (IGF-I) response for
approximately 5 days after a single dose.8 LB03002
has recently been demonstrated to have comparable
efficacy to daily rhGH when administered at higher
total rhGH in both GHD children9 and adults.10
PEGylation (the attachment of polyethylene gly-
col, PEG) has also been used to extend the half-life
of rhGH enabling weekly dosing. The first PEGylated
rhGH studied in GHD patients (PHA-794428) caused
local injection-site lipoatrophy in GHD children re-
sulting in safety concerns11 and discontinuation of its
development. A similar PEGylated rhGH (NNC126-
0083) does not provide sustained pharmacodynamics
responses for 1 week after administration in GHD
children12 and is no longer being developed.
A limitation of hGH therapies and long-acting
forms of rhGH such as PEGylated rhGH products
is the two clearance mechanisms for hGH, glomeru-
lar filtration and receptor-mediated clearance in the
kidneys.13–16 PEGylated or other modified forms of
hGH are not subject to glomerular filtration. How-
ever, these modified forms are still able to bind the
hGH receptor in the kidney and undergo endocytosis.
After endocytosis in the kidney, the hGH or modi-
fied hGH may be completely or partially metabolized
by proteases resulting in excretion of the breakdown
products.
VRS-317 was designed to reduce the clearance of
rhGH from the body by both glomerular filtration
and receptor-mediated clearance using XTEN tech-
nology. XTEN technology uses long unstructured hy-
drophilic sequences of amino acids to increase the
half-life of peptides and proteins.17 A long N-terminal
XTEN sequence is added to rhGH as a fusion protein,
increasing the hydrodynamic size of the rhGH, and
thereby, reducing glomerular filtration. A C-terminal
XTEN sequence is also added to potentially reduce
receptor-mediated clearance by decreasing receptor
binding. VRS-317 was designed with the identical
rhGH sequence present in approved rhGH products,
and therefore, contains the identical high- and low-
affinity receptor binding epitopes present in approved
rhGH products.
MATERIAL AND METHODS
Cloning of VRS-317
First, a long XTEN polypeptide (XTEN1) was in-
troduced into the pET30 plasmid (EMD Millipore,
Madison, Wisconsin). The hGH gene, corresponding
to the native hGH sequence, was amplified by poly-
merase chain reaction and cloned into the above
plasmid at the C-terminus of the XTEN gene. To
generate the final VRS-317 expression construct, a
short XTEN polypeptide (XTEN2; 13.3 kDa) was ap-
pended to the C-terminus of the hGH gene. The final
construct, XTEN1–hGH–XTEN2, was transformed
into BL21-Gold(DE3), where expression of the fu-
sion protein, VRS-317, could be induced with the ad-
dition of isopropyl-$-D-1-thiogalactopyranoside. The
XTEN1–rhGH (105.6 kDa) construct was cloned with
the same methodology without the addition of the
XTEN2.
Expression and Purification of VRS-317 and
XTEN1-rhGH
VRS-317 was expressed in the cytoplasm of Es-
cherichia coli as a soluble fusion protein-containing
hGH with XTEN1 at the N-terminus and a XTEN2
at the C-terminus. The sequence of rhGH in VRS-
317 was identical to human-pituitary-derived hGH
(somatotropin). The soluble product was initially re-
covered by lysis of the host cells. The majority of the
host cell proteins and microbial DNA were selectively
precipitated by adjusting the pH of the lysate to 4.5
with acetic acid. The acidified lysate was then clari-
fied by a combination of centrifugation and filtration.
VRS-317 was then purified by weak anion-exchange
chromatography at pH 4.5. Following weak anion-
exchange chromatography, the pH of the pooled elu-
tion fractions was adjusted to 4.2, the conductivity
of the feed was reduced by dilution with water, and
then further purified by cation-exchange chromatog-
raphy. The cation-exchange elution fractions were di-
luted and the pH was adjusted to greater than 7.5.
Product-related aggregates were resolved from the
product with additional anion-exchange purification.
Finally, the product was formulated and concentrated
using tangential flow filtration.
XTEN1–rhGH was also produced usng a similar
process as described above.
Biophysical Characterization of VRS-317
Nonreducing sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) analysis of VRS-317
was performed on NuPAGE Bis–Tris 4%–12% poly-
acrylamide gels (Life Technologies, Carlsbad, Califor-
nia) using NuPAGE MES SDS Running Buffer (Life
Technologies). Size exclusion high-performance liq-
uid chromatography (HPLC) analysis of VRS-317 was
performed on a BioSEP-SEC-S 4000 7.8 × 600mm2
column (Phenomenex, Torrance, California) using
a Shimadzu HPLC system (Shimadzu, Columbia,
Maryland).
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In Vitro Receptor Binding
To evaluate the binding affinity of the XTEN1–rhGH
fusion proteins, including VRS-317, a receptor bind-
ing enzyme-linked immunosorption assay (ELISA)
was performed. The wells of a Costar 3690 plate were
coated with 2:g/mL of recombinant human growth
hormone receptor Fc chimera (hGHR-Fc; R&D Sys-
tems, Minneapolis, Minnesota), and then thoroughly
blocked with a solution of 3% bovine serum albu-
min (BSA) in phosphate-buffered saline (PBS). Puri-
fied XTEN1–rhGH or VRS-317 was serially diluted
in Binding Buffer (PBS containing 0.05% Tween-
20 and 1% BSA), and incubated on the hGHR-Fc
coated wells for at least 1 h at room temperature.
Unbound XTEN1–rhGH or VRS-317 was removed by
washing with PBS containing 0.05% Tween-20. A bi-
otinylated polyclonal antihGH antibody was used to
detect the bound XTEN1–rhGH or VRS-317. Strepta-
vidin–horseradish peroxidase (HRP) was then added,
excess removed by washing, and bound amount
measured by colorimetric change after addition of
a 3,3′,5,5′-tetramethylbenzidine (TMB) peroxidase
substrate.
Potency Assay
The procedure uses a murine pro-B cell line (BaF/
803) that has been stably transfected using hGHR
cDNA and pNeo plasmid.18 This cell line designated
BaF/hGHR/B2B2, expresses approximately 3000 sur-
face hGH receptors per cell, and is hGH responsive
(as measured by the stimulation of cellular division).
Growth and maintenance of this cell line require the
inclusion of either rhGH or interleukin 3 into the
media during passaging. The mitogenic response to
rhGH is quantified by alamar Blue R© to detect the
proliferation of the BaF/hGHR/B2B2 cells. The effec-
tive concentration to cause 50% of maximum growth
(EC50) over 2 days is determined from a minimum
of eight different concentrations of the test sample or
the positive control, rhGH, in triplicate.
PK Experiments
All animal experiments were performed with the ap-
proval of MPI Research’s Institutional Animal Care
and Use Committee and in accordance with accepted
standards of humane animal care. Male Sprague–
Dawley rats (six per group) were dosed s.c. with
0.3mg/kg (13.5 nmol/kg) rhGH, 1.5mg/kg (13.2 nmol/
kg) XTEN1–rhGH, or 1.5mg/kg (12.6 nmol/kg) VRS-
317. XTEN1–rhGH and VRS-317 were dosed intra-
venously (i.v.) tomeasure the terminal half-life of each
protein.
Male cynomolgus monkeys (four per group) were
used to assess the PK of the XTEN1–rhGH and VRS-
317 after a single s.c. dose of 5mg/kg XTEN1–rhGH
(44.1 nmol/kg) or VRS-317 (42.1 nmol/kg). The plasma
samples were taken at predose and at selected time
points up to 14 days postdose.
The rate of absorption and bioavailability (abso-
lute) of VRS-317 after s.c. or intramuscular (i.m.) in-
jection was determined in male cynomolgus monkeys
(three to four per group) after dosing with 1.5mg/
kg (12.6 nmol/kg) VRS-317 by i.v., i.m., or s.c. ad-
ministration. Plasma samples were taken predose
and at selected time points postdose up to 21 days
(504h).
To assess dose linearity, cynomolgus monkeys were
assigned to groups of six to eight males and six to
eight females, each receiving s.c. injections of placebo
or 1, 5, or 25mg/kg VRS-317 every 2 weeks for a to-
tal of eight injections as part of a good laboratory
practice (GLP) toxicology study. Blood samples were
collected from animals before dosing and at 0.25, 1,
2, 6, 12, 24, 48, 96, 168, 240, and 312h after the first
dose.
Plasma VRS-317 concentrations were determined
by Intertek Alta Analytical Laboratory (San Diego,
California) using a validated ELISA with a range
of 1–500ng/mL. Plasma concentrations versus time
curves were generated for each animal. All PK data
were then plotted as a mean and standard deviation
for each group of animals receiving the same dose of
VRS-317 (or rhGH). Noncompartmental analysis was
performed with WinNonlin professional version 5.2.1
(Pharsight Corporation, St. Louis, Missouri). Concen-
trations below the quantitation limit of the assaywere
set to zero for the estimation of parameters. The area
under the curve from time zero to the last measur-
able time point (AUC0–t) was estimated using the lin-
ear trapezoid method. Linear regression over the last
three or more time points was used to estimate the
elimination rate constant, which was used to estimate
terminal half-life (t1/2) and AUC from zero to infinity
(AUC0–∞). The maximum concentration (Cmax) and
the time it was observed (Tmax) were determined di-
rectly from the data.
ELISAs for PK
A quantitative sandwich ELISA technique was de-
veloped to measure VRS-317 or XTEN1–rhGH in
rat and cynomolgus monkey plasma. In the assay,
standards, controls, and test samples are incubated
with anti-XTEN immunoglobulin G antibody that has
been immobilized on a microtiter plate. After incuba-
tion, unbound material is washed away and VRS-317
or XTEN1–rhGH is detected using biotinylated goat
anti-human GH antibody followed by streptavidin–
HRP and visualized with a TMB peroxidase sub-
strate. The assay has a range of 1–500ng/mL.
rhGH PK was determined from plasma samples
using an ELISA Kit purchased from R&D Systems.
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Hypophysectomized Rat Studies
Sprague–Dawley male rats weighing 70–100 g (six
per group) had their pituitaries surgically removed.
The placebo, rhGH, and VRS-317 were administered
via a s.c. injection in the cervical region on the dorsal
surface. Body weights were measured and recorded
daily for several days before dosing. Rats were ran-
domized into treatment groups to insure balance for
average body weight across the groups.
Necropsy examinations were performed under pro-
cedures approved by a veterinary pathologist on all
animals to determine the level of pituitary ablation
due to the surgery. Both tibias were collected from
all animals and fixed in 10% neutral buffered for-
malin, decalcified, embedded in paraffin, sectioned
with a microtome into approximately 4:m sections,
stained with toluidine blue and examined with a light
microscope. Each tibia was cut at five progressive
levels at approximately 150–200:m intervals, thus,
yielding five epiphyseal sections for measurements.
Data were examined by analysis of variance with
a Tukey–Kramer posthoc test for pairwise compar-
isons using JMP software (SAS Institute, Cary, North
Carolina) and a p value of 0.05.
Juvenile Cynomolgus Monkey Study
Young adult (approximately 2 years of age) cynomol-
gus monkeys were assigned to one of four treatment
groups (two males/two females per group). VRS-317
was administered 0.4 or 1.4mg/kg on Days 1, 29,
and 57. Additional groups received placebo or rhGH
(Saizen R©; Merck-Serono, Geneva, Switzerland) at a
dose of 0.05mg/kg daily from Days 1 to 28. A dose vol-
ume of 0.28mL/kg was employed in each of the VRS-
317 dose groups, whereas the rhGH group was dosed
at a volume of 0.05mL/kg. During the study, cageside
observations were recorded daily, body weights were
measured weekly, and the injection site was evalu-
ated and scored for erythema and edema at times,
which corresponded with blood collections for PK at
several time points (predose and up to 672h postdose).
Blood was collected from VRS-317 animals for clin-
ical pathology evaluations (hematology and/or clin-
ical chemistry) pretreatment and 24h after dosing
on Days 1, 29, and 57 and on Day 85. Two 5mm
punch biopsies of injection sites were obtained from
animals treated with VRS-317, 5 days following dos-
ing on Days 29 and 57. Fat content from the injection
sites was evaluated and graded. The PK of rhGH and
VRS-317 was measured after the first and last dose.
IGF-I and IGF binding protein 3 (IGFBP-3) analyses
were performed at several time points between each
dose and after the last dose. Body weight and food
consumption was monitored daily. Immune responses
(antibodies) to VRS-317, hGH, and XTEN were mea-
sured prestudy, during study, and at completion of the
study (Day 85).
Pharmacodynamic Assays
Insulin-like growth factor I analysis for adult
cynomolgus monkeys was performed on plasma sam-
ples after acid ethanol extraction using an immunoas-
say in a Luminex R© bead format (Milliplex IGF-1
kit; EMD Millipore Corporation, Billerica, Mas-
sachusetts). IGF-I and IGFBP-3 analyses for ju-
venile cynomolgus monkeys were performed using
an immunoassay (Siemens Immulite 2000; Pacific
Biomarkers, Inc., Seattle, Washington).
The dose proportionality of the pharmacodynamics
response to VRS-317 was studied after s.c. adminis-
tration in male cynomolgus monkeys. Monkeys (n =
4/group) were dosed with 0.3, 1.5, or 7.5mg/kg VRS-
317 (2.5, 12.6, and 63nmol/kg, respectively). Plasma
samples for IGF-I levels were taken predose and at se-
lected time points up to 21 days (504h) postdose. The
response to treatment (VRS-317 or rhGH) was calcu-
lated using each animals baseline IGF-I or IGFBP-3
and the percent increase from baseline in each an-
imal. All pharmacodynamic data were then plotted
as a mean and standard deviation for each group of
animals receiving the same dose of VRS-317 or rhGH.
Safety Assessment in Cynomolgus Monkeys
A total of 28 male (3.15–4.2 kg) and 28 female
(2.2–2.7 kg) naı¨ve cynomolgus monkeys were as-
signed to groups to receive s.c. injections of placebo
or VRS-317 every 2 weeks for a total of eight injec-
tions. Four groups of three animals per sex per group
received the placebo or VRS-317. The dose levels of
0, 1.0, 5.0, and 25.0mg/kg VRS-317 were given at
respective dose volumes of 0.758, 0.030, 0.152, and
0.758mL/kg. Two additional animals of each sex were
included in the placebo and 25.0mg/kg dose group for
a 28-day recovery period following the dosing period
to assess the persistence, reversibility, and/or delayed
occurrence of any potential treatment effects. The dos-
ing formulations were injected between the skin and
underlying layers of tissue to one of two injection sites
in the scapular region on the back of each animal, ro-
tating the injection sites at each dose.
Observations for morbidity, mortality, injury, and
the availability of food and water were conducted
twice daily. Detailed clinical observations (includ-
ing an evaluation of injection sites) were conducted
weekly. Body weights were measured and recorded
weekly beginning Day −1. Ophthalmoscopic exam-
inations were conducted pretest and before each
necropsy.
Physical examinations were conducted pretest.
Electrocardiographic examinations and respiration
rate determinations were conducted pretest and at
approximately 1–2h postdose on Day 99. Blood and
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urine samples for clinical pathology evaluations were
collected pretest and on Days 100 and 128. At
necropsy on Days 100 and 128, macroscopic examina-
tions were performed, organ weights were recorded,
and a comprehensive list of tissues was collected for
microscopic examination from all animals terminated
on Day 100 and the injection site on Day 128.
Pig Lipoatrophy Study
Four healthy naı¨ve female Sinclair miniature swine
were acclimated for at least 3 days before assignment
to this study. Each animal assigned to study received
s.c. injections of a placebo, 1.0mg rhGH, and 5.4 and
27mg VRS-317 to separate injection areas designated
on the dorsal area of the animal. Following the initial
injections, injections of 1.0mg rhGH were adminis-
tered to all animals at approximately 8h intervals for
the duration of the study. PK blood samples and skin
biopsies were collected up to 120h from the initial
injection. Animals were sacrificed following their fi-
nal designated blood and biopsy collection time point.
Biopsy samples were measured by quantitative mor-
phometry and histomorphometry.
RESULTS
Expression and Purification
VRS-317 (XTEN1–rhGH–XTEN2) was expressed as a
fusion protein of rhGH and hydrophilic, unstructured
amino acids, XTEN. The XTEN domains of VRS-317
increased the solubility and stability of the rhGH do-
main. Unlike rhGH, VRS-317 was soluble in the cy-
toplasm of E. coli and no inclusion bodies were ob-
served. Purification was facilitated by the increased
acid stability of VRS-317. After cell lysis, treatment
with acetic acid caused precipitation of most host cell
proteins with minimal VRS-317 loss. The negative
charge from the glutamate residues in the XTEN do-
main resulted in a pI of approximately 3 for VRS-
317, as compared with the pI of 5.2 for rhGH.19 These
properties enabled the use of ion-exchange methods
to remove host cell proteins, DNA, and aggregates
of VRS-317. As shown in Figure 1, the final purified
material was a single band on a nonreducing SDS-
PAGE gel slightly larger than its calculated molec-
ular weight (MW) of 119kDa and did not contain
aggregates as measured by size exclusion chromatog-
raphy. The large size and unstructured nature of the
XTEN domains provide a large hydrodynamic ra-
dius as noted by the early elution time in the size
exclusion chromatogram,17 as confirmed by size ex-
clusion chromatography with multiangle light scat-
tering (112,290Da; data not shown). The large hy-
drodynamic radius introduced by the XTEN sequence
and the low pI of VRS-317 also cause VRS-317 to mi-
grate less than the globular protein markers on the
Figure 1. (a) SDS-PAGE of 2, 5, and 10:g of VRS-317
compared with a molecular weight marker. (b) Size exclu-
sion HPLC analysis of VRS-317 (solid curve) compared with
a set of globular molecular weight standards (dashed curve,
Bio-Rad Laboratories, Hercules, California). The standard
includes thyroglobulin 670kDa, gamma-globulin 158kDa,
ovalbumin 44kDa, myoglobin 17kDa, and vitamin B12
1.35kDa. The formulation buffer for VRS-317 elutes at
25mL.
SDS-PAGE gel (e.g., gamma-globulin, 158kDa, pI ∼
6.9). The XTEN1–rhGH construct was expressed and
purified yielding a similar high-purity fusion protein
for further characterization.
Molecule Optimization
An early construct of VRS-317 was designed to max-
imize the binding to the hGH receptor in vitro. This
construct was a fusion protein of a long XTEN se-
quence at the N-terminus (83.6 kDa) and rhGH at
the C-terminus (XTEN1–rhGH; 105.6 kDa). To as-
sess the impact of reduced receptor binding, a short
XTEN domain (XTEN2; 13.3 kDa) was added to the C-
terminus of rhGH along with the long XTEN (XTEN1)
domain at the N-terminus. There was no significant
effect of the long N-terminal XTEN (XTEN1–rhGH)
on binding affinity when compared with rhGH in an
ELISA-based receptor binding assay. However, VRS-
317 (XTEN1–rhGH–XTEN2) had an approximately
11-fold reduction in affinity (IC50= 27nM) compared
with rhGH (IC50= 2.5 nM) (Fig. 2a). The ability of
VRS-317 to bind to two hGH receptors and cause
dimerization that results in intracellular signaling
was tested using a cell line engineered to proliferate in
response to rhGH. In this in vitro potency assay, the
EC50 of VRS-317 was 12-fold (6.8 nM) greater than
rhGH (0.6 nM) indicating a lower in vitro potency for
VRS-317 (Fig. 2b).
Because the XTEN constructs had significantly
largermolecular mass than rhGH, the analyses below
were performed using both mass (mg/kg) and molar
(nmol/kg) dosing to provide an estimate of the rhGH
dose administered in each case (rhGH MW: 22kDa).
VRS-317 (119kDa) had a molecular mass approxi-
mately fivefold greater than rhGH.
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Figure 2. (a) Receptor-binding ELISA results for
rhGH(; dashed line), XTEN1–rhGH (), and VRS-317 ().
(b) In vitro cell-based potency assay results for rhGH (;
dashed line) and VRS-317 () [relative fluorescence units
(RFU) measuring number of viable cells].
Pharmacokinetics
To assess the PK of VRS-317 andXTEN1–rhGH, stud-
ies were performed in rats and monkeys (Fig. 3). Rats
were dosed s.c. with approximately equal molar doses
of rhGH, XTEN1—rhGH, or VRS-317. In addition,
XTEN1–rhGH and VRS-317 were dosed i.v. to mea-
sure the t1/2 of each protein. As shown in Figure 3a,
rhGH has a rapid clearance after s.c. administration.
XTEN1–rhGH and VRS-317 had a slower absorption
phase, greater Cmax, and a longer t1/2 than rhGH.
The terminal elimination half-lives of XTEN1–rhGH
and VRS-317 determined after i.v administration
in rats were 6.8 and 15h, respectively. The PK of
XTEN1–rhGH and VRS-317 was also determined in
monkeys after a single s.c. dose. As shown in Fig-
ure 3b, both the XTEN1–rhGH and VRS-317 achieved
a similar Cmax within 48h postdose, but VRS-317 had
a significantly longer half-life (XTEN1–rhGH: 48.6 h;
VRS-317: 110h).
Figure 3. (a) Pharmacokinetics in rats after subcu-
taneous (s.c.) administration of 0.3mg/kg (13.5 nmol/kg)
rhGH (), 1.5mg/kg (13.2 nmol/kg) of XTEN1–rhGH (;
dashed line), or 1.5mg/kg (12.6 nmol/kg) of VRS-317 ().
(b) The pharmacokinetics of XTEN1–rhGH (; dashed line;
44.1 nmol/kg) and VRS-317 (, 42.1 nmol/kg) after a single
5mg/kg s.c. injection in adult cynomolgus monkeys.
To determine the rate and extent of absorption of
VRS-317 after s.c. or i.m. injection, the PK of VRS-317
was studied in monkeys after i.v. (n= 4), s.c. (n= 3) or
i.m. (n= 3) administration of 1.5mg/kg (12.6 nmol/kg)
VRS-317. VRS-317 was rapidly absorbed after either
s.c. or i.m. administration (Fig. 4). The Cmax relative
to that following i.v. injection was 78.5% and 89% for
s.c. and i.m., respectively. The bioavailability based
on AUC0–t was 101% and 103% for s.c. and i.m., re-
spectively. These results demonstrated that VRS-317
was rapidly and near completely absorbed after s.c.
administration.
The dose proportionality of the PKs of VRS-317
was studied after s.c. administration in cynomolgus
monkeys as part of a safety study. The PK profile of
VRS-317 after single s.c. administration to monkeys
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Figure 4. (a) Pharmacokinetics of 1.5mg/kg (12.6 nmol/
kg) of VRS-317 in cynomolgus monkeys dosed either intra-
venously (i.v.; ), subcutaneously (s.c.; ) or intramuscu-
larly (i.m.; ). (b) Same results shown for first 24h after
dosing.
was approximately linear with dose (Table 1). These
results indicate that the absorption and clearance of
VRS-317 was not dependent upon dose level between
1 and 25mg/kg (8.4–210nmol/kg).
Repeat dose PK was evaluated in juvenile cynomol-
gus monkeys (two per sex per group) administered
s.c. doses of 0.4 or 1.4mg/kg (3.4 or 11.8 nmol/kg)
VRS-317 every 28 days or 0.05mg/kg/day rhGH for
28 days. The PKs of VRS-317 were determined af-
ter each dose and the PKs of rhGH were determined
after first (Day 1) and last (Day 28) dose as shown
Figure 5. (a) Pharmacokinetics of VRS-317 dosed s.c. at
0.4 () or 1.4 () mg/kg (3.4 or 11.8 nmol/kg) VRS-317
every 28 days in juvenile cynomolgus monkeys (genders
combined). (b) Pharmacokinetics of 0.05mg/(kg day) rhGH
dosed s.c. in juvenile cynomolgus monkeys after first (Day
1; ) and last dose (Day 28; ).
in Figure 5. A consistent and dose proportional Cmax
(0.4mg/kg: 40 ± 17nM; 1.4mg/kg: 100 ± 34.5 nM)
was noted after each administration. No accumula-
tion was noted on the basis of comparable Cmax and
exposure (AUC-0.4mg/kg: 4440 ± 1209nM-h; 1.4mg/
kg: 16800 ± 3586nM-h) after each administration.
Pharmacodynamics
Weight gain in a hypophysectomized-rat-adminis-
tered daily rhGH for 6 or 7 days was the standard
Table 1. Pharmacokinetic Parameters (Mean ± SD) Estimated by Noncompartment Methods After Single
Subcutaneous Doses of VRS-317 in Cynomolgus Monkeys
Dose (mg/kg) (nmol/kg) Cmax (:g/mL) Cmax (nM) AUC0–∞ (:g h/mL) AUC0–∞ (nM h)
1 (8.4) 24.8 ± 13.5 208 ± 114 2046 ± 488 17, 190 ± 4099
5 (42) 98.8 ± 65.2 830 ± 548 11, 004 ± 3861 92, 471 ± 32, 441
25 (210) 476 ± 236 3, 999 ± 1985 87, 911 ± 26, 155 738, 751 ± 219, 787
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Table 2. Potency Assessment of Different Doses and Regimens of VRS-317 Compared with rhGH and Placebo in
Hypophysectomized Rats
Dose (mg/kg)
[hGH equiv mg/kg]
Dose
(nmol/kg) Dosing Frequency
Total Dose
(nmol/kg) Cssa (nM)
Body Weight Gain
(g; ±SD)–Day 7
Tibial Epiphyses
Width (:m; ±SD)
Experiment 1
Placebo 0 Days 1, 3, 5, and 7 NAb NA 0.8 ± 1.1 617 ± 158
rhGH control: 0.1 5 Daily 35 NA 10.7 ± 0.8∗ 905 ± 51∗
VRS-317: 5.40 [1.0] 45 Days 1 and 5 90 57.1 13.7 ± 1.1∗ 915 ± 60∗
VRS-317: 1.35 [0.25] 11 Days 1, 3, 5, and 7 44 10.0 14.3 ± 1.1∗ 917 ± 39∗
VRS-317: 0.34 [0.06] 3 Days 1, 3, 5, and 7 12 1.34 9.7 ± 2.3∗ 854 ± 80∗
Experiment 2
Placebo 0 Daily (1–6) NA NA 2.0 ± 2.4 574 ± 152
rhGH control: 0.1 5 Daily (1–6) 30 NA 12.3 ± 4.5 884 ± 262∗
VRS-317: 0.34 [0.06] 3 Days 1, 3, and 5 9 1.34 15.2 ± 7.3∗ 1046 ± 316∗
VRS-317: 0.057 [0.01] 0.5 Daily (1–6) 3 0.54 4.8 ± 1.2 731 ± 197
VRS-317: 0.17 [0.03] 1.5 Daily (1–6) 9 1.63 15.3 ± 5.6∗ 1101 ± 308∗
aCss, steady-state VRS-317 concentration calculated from mean of simulated PK for Day 1–7 (Day 1, first dose day).
b NA, Not Applicable.
∗Significantly different from placebo, p < 0.05.
historical method for assessment of rhGH potency. To
assess the in vivo potency of VRS-317, different dose
regimens of VRS-317 were compared with a fixed dose
of daily rhGH in hypophysectomized rats dosed s.c.
In the first experiment, VRS-317 dosed every other
day at 0.34mg/kg (12nmol/kg total) produced the
same total weight gain as daily dosing of 0.10mg/
kg hGH (35nmol/kg total). There was also no differ-
ence in the thickness of the tibial epiphyses between
the two treatment groups (Table 2). Higher doses of
VRS-317 produced an increased weight gain and tib-
ial epiphyses thickness compared with daily rhGH
treatment. These results indicated a greater in vivo
potency of VRS-317 relative to rhGH on amolar basis.
In addition, VRS-317 demonstrated a direct effect on
bone growth in this model.
To evaluate the relationship between VRS-317
plasma levels and potency in hypophysectomized
rats, an additional dose ranging study was per-
formed comparing lower doses of VRS-317 with daily-
administered rhGH. A total dose of 1mg/kg (9 nmol/
kg) of VRS-317 [3 nmol/kg every other day or 1.5 nmol/
kg per day] produced a weight gain slightly greater
than a total hGH dose of 35nmol/kg (Experiment 2,
Table 2). Similar effects were also noted on the thick-
ness of tibial epiphyses after sacrifice of the rats on
Day 7. Using single dose PK data following s.c. admin-
istration of VRS-317 or rhGH in rats, the relationship
between plasma exposure and efficacy in hypophy-
sectomized rats was modeled to calculate the steady-
state plasma concentration (Css) of VRS-317. These
results indicate that sustaining a level of VRS-317
above 1nM provides a growth response comparable
to a daily dose of rhGH in hypophysectomized rats.
The effect of sustained VRS-317 exposure com-
pared with daily rhGH administration was also as-
sessed in juvenile cynomolgus monkeys. As shown
in Figure 6, 1.4mg/kg (11.8 nmol/kg) VRS-317 stim-
ulated an IGF-I and IGFBP-3 response compara-
ble to 0.05 mg/kg/day rhGH in juvenile cynomolgus
monkeys over 28 days (Total rhGH dose: 1.4mg/kg
or 64nmol/kg). The pharmacodynamic response was
achieved at approximately a sixfold lower molar dose
than daily hGH indicating that the sustained levels of
VRS-317 stimulated the pharmacodynamic response
continuously over the 28 days. The reduced phar-
macodynamic response noted around 14 days after
dosing of 0.4mg/kg (3.4 nmol/kg) VRS-317 correlated
with the plasma levels of VRS-317 decreasing below
1nM (119ng/mL VRS-317; Fig. 5a).
A similar IGF-I response was noted in adult
cynomolgus monkeys (four males per group) adminis-
tered a single s.c. dose of VRS-317. A dose dependent
increase in IGF-I levels was noted in monkeys admin-
istered 0.3, 1.5, or 7.5mg/kg (2.5, 12.6, or 63nmol/
kg, respectively) VRS-317 with mean maximum in-
creases above baseline (predose) of 71%, 204%, and
335%.
Safety Assessment of VRS-317
To date, VRS-317 has been administered to rats, pigs,
and monkeys as single doses and to rats and monkeys
as repeat doses up to 25mg/kg (63nmol/kg). No ob-
servable clinical signs or symptoms have been noted
in these studies.
In the juvenile cynomolgus monkey study, no test
article-related effects among lipid parameters were
identified in any group at any interval. All individual
animal variations were considered to be within the
range of normal biologic variability for this species.
Therefore, no adverse effects were noted in monkeys
dosed with 0.40 or 1.4mg/kg VRS-317 every 28 days
for 84 days. At Day 85, two monkeys dosed 1.4mg/
kg VRS-317 developed low titer antibodies against
VRS-317 that were specific to the rhGH domain. This
antibody response was probably caused by the lack
of homology between cynomolgus GH and rhGH. No
anti-XTEN antibodies were detected. There were no
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Figure 6. IGF-I (a) and IGFBP-3 (b) changes from base-
line in juvenile cynomolgus monkeys after administration
of placebo (×), 0.05mg/(kg day) rhGH for 28 days (; 1.4mg/
kg rhGH; 64nmol/kg), 0.40 () or 1.4mg/kg (; 3.4 or
11.8 nmol/kg, respectively) VRS-317 as single s.c. injection.
detectable differences in VRS-317 PK or the pharma-
codynamics response in these monkeys, suggesting
that the low titer antibody responses did not have a
significant clinical effect.
In the 14-week GLPmonkey toxicology study, mon-
keys were administered placebo or 1, 5, or 25mg/kg
VRS-317 every other week. There were no VRS-317-
related effects on the following parameters: clinical
observations, dermal irritation scores, body weights,
ophthalmoscopic examinations, respiratory rate, elec-
trocardiographic parameters, coagulation parame-
ters, clinical chemistry analytes, urinalysis param-
eters, macroscopic observations, or organ weights.
There were no adverse histopathology changes at-
tributed to VRS-317. In particular, no significant dif-
ferences in glucose or lipid metabolism, mammary
or prostate tissues, or brain tissues were noted be-
tween placebo and VRS-317 treated animals. None of
the effects noted during this study were considered
adverse. Therefore, the No-Observed-Adverse-Effect
Level (NOAEL) for this study was 25.0mg/kg per dose
of VRS-317. The proposed highest dose in the ongoing
single administration Phase 1 trial in adult GHD pa-
tients is 0.8mg/kg (based on a 70kg human), which on
a human equivalent dose basis is approximately 10-
fold below the NOAEL established in this repeat-dose
toxicology study in monkeys.
Because lipoatrophy has been noted for PEGylated
rhGH, the potential for lipoatrophy caused by s.c. ad-
ministration of VRS-317 was extensively studied in
pigs andmonkeys. Four healthy naı¨ve female Sinclair
miniature swine were injected s.c. at three injection-
site grids per pig (12 total grids). In each injection-
site grid, there was a placebo control, an rhGH con-
trol (injected every 8h), 20mg methylprednisolone,
or 5.4 or 27mg of VRS-317. Injection sites were har-
vested by biopsy from 24 to 96h postdose. Histol-
ogy and histomorphometry were conducted on each
biopsy sample. There were no visible changes except
for the rhGH control in which inflammation and tis-
sue damage resulted from repeated injections. There
was no significant lipoatrophy observed for any of the
treatments at any of the time points by morphometry.
These data suggest that VRS-317 does not cause overt
lipoatrophy.
No lipoatrophy has been noted following the admin-
istration of VRS-317 in the monkey studies conducted
to date. Injection-site biopsies from the repeat dose ju-
venile monkey study were analyzed to further assess
the potential for VRS-317 to cause lipoatrophy. The fat
content of skin biopsies from the injection sites was
quantitatively evaluated. Differences in fat content
appeared related to individual and/or sampling vari-
ations, and there were no discernible VRS-317 and/
or time effect. Overall the qualitative evaluation cor-
related to the quantitative histomorphometric eval-
uation. In addition, injection-site analyses from the
14-week GLP monkey toxicology study also did not
reveal any notable lipoatrophy.
DISCUSSION
Previous attempts to develop long-acting rhGH prod-
ucts focused on either continuous delivery of native
rhGH or modifications such as PEGylation without
altering the binding of rhGH to its receptor. These
approaches only achieved short-term (weekly or less)
rhGH exposure and subsequently lower pharmacody-
namic (e.g., IGF-I) and/or growth responses.
By contrast, VRS-317 was designed to have a
lower affinity for the hGH receptor, thereby reducing
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receptor-mediated clearance and, in turn, potentially
minimizing side effects such as lipoatrophy. By at-
taching the hydrophilic amino acid sequences, XTEN,
to the N-terminus (XTEN1) and C-terminus (XTEN2)
of rhGH, the receptor binding and cell-based po-
tency of VRS-317 was reduced approximately 11–12-
fold compared with rhGH (Fig. 2). By contrast, the
XTEN1–rhGH construct with only XTEN on the N-
terminus of rhGH had comparable receptor binding
to rhGH (Fig. 2a). The increased half-life of VRS-317
compared with XTEN1–rhGH (Fig. 3) cannot be ex-
plained by the small difference in molecular mass
(VRS-317: 119kDa; XTEN1–rhGH: 105.6 kDa) and
may be the result of the reduction in receptor bind-
ing for VRS-317 compared with XTEN1–rhGH. These
studies demonstrated that reducing rhGH binding
affinity increased terminal elimination half-life.
A concern with reduced in vitro potency was the
potential need for higher doses of VRS-317 compared
with rhGH. However, the molar potency in vivo of
VRS-317 was at least threefold greater than daily
rhGH as noted by the bone growth and weight
gain in hypophysectomized rats (Table 2). A fivefold
lower molar dose of VRS-317 was required to pro-
vide sustained pharmacodynamic responses (IGF-1
and IGFBP-3) compared with daily rhGH in juvenile
rhesus monkeys (Fig. 6). These studies indicated that
a lower rhGH dose in the form of VRS-317 was re-
quired to invoke pharmacodynamic and growth re-
sponses presumably because of the longer tissue ex-
posure time to rhGH when administered as VRS-317.
The PK of VRS-317 was dose proportional (Table
1) and reproducible (Fig. 4), allowing for evaluation
of the relationship between the plasma concentration
of VRS-317 and the biological responses. Sustaining
a VRS-317 at 1nM or above was sufficient to achieve
a sustained growth response in hypophysectomized
rats (Table 2) and pharmacodynamic responses in
monkeys (Fig. 6). The magnitude of the pharma-
codynamic responses in monkeys was dose propor-
tional ensuring that a dose ranging study in humans
may allow for accurate prediction of an efficacious
dose.
Historical studies of other rhGH formulations as
well as continuous infusion studies have indicated
that transient glucose and lipid metabolism changes
may occur.4,5 In a 14-week GLP toxicology study in
adult monkeys and a 12-week study in juvenile mon-
keys, there were no observed changes in these clini-
cal parameters. Only low-titer hGH-specific immune
responses that did not affect the PK or pharmaco-
dynamics of VRS-317 were noted after repeated dos-
ing (juvenile monkeys 1.4mg/kg VRS-317 every 28
days). In addition, VRS-317 was well tolerated at the
maximum dose administered (25mg/kg) every other
week in the GLP toxicology study with no observable
adverse effects noted by detailed and comprehensive
clinical observations or detailed histological examina-
tions.
Other long-acting forms of rhGH have caused
injection-site lipoatrophy.11 The lipoatrophy may
have occurred because of a sustained s.c. exposure
to rhGH, which stimulates lipolysis. VRS-317 has re-
duced affinity for the hGH receptor, and therefore,
may bind less to the local hGH receptors in the s.c.
tissues. In addition, VRS-317 was rapidly absorbed
after s.c. administration reducing the potential for
lipoatrophy. A lipoatrophy study was conducted in
pigs and no lipoatrophy was noted with VRS-317. In
addition, no lipoatrophy has been noted to date in the
monkey studies, some of which included injection-site
histology.
Overall, VRS-317 is a novel rhGH construct with
the potential to be administered up to monthly in
GHD adults and children at total monthly doses lower
than the typical daily rhGH. VRS-317 may lead to
increased compliance and convenience in GHD pa-
tients resulting in improvements in therapeutic ben-
efits without increased safety concerns.
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